Scientific research trends

Visiting professor cancer cell of Suzhou University publishes new achievements in cancer research

Publishdate:2019-08-29 Views:151

[introduction] researchers from the school of medicine, University of Pittsburgh and Suzhou University confirmed in a new study that il-36 γ can transform tumor microenvironment and promote type 1 lymphocyte mediated anti-tumor immune response. This important finding was published in the August 27 issue of cancer cell.

Researchers from the University of Pittsburgh School of medicine and Suzhou University confirmed in a new study that il-36 γ can transform the tumor microenvironment and promote the type 1 lymphocyte mediated anti-tumor immune response. This important finding was published in the August 27 issue of cancer cell.

Dr. Binfeng Lu, visiting professor at Suzhou University and associate professor of immunology at the University of Pittsburgh School of medicine, is the corresponding author of this paper. Professor Lu is mainly engaged in tumor immunology research and has published more than 50 papers in science, Nature Immunology, immunology, PNAs and other world-class academic journals.

Cancer, as one of the most deadly killers of human health, has always been a difficult problem for scientists and doctors to overcome. With the increasing environmental problems, the incidence rate of cancer is increasing. Recently, tumor immunotherapy has become the focus of tumor therapy.

In recent years, the good news of tumor immunotherapy continues. At present, it has shown strong antitumor activity in the treatment of some tumor types, such as melanoma, non-small cell lung cancer and so on, and has been approved by FDA for clinical application. Tumor immunotherapy was named as the most important scientific breakthrough of the year by science in 2013 due to its excellent efficacy and innovation. It is expected to become an innovation in the field of tumor treatment after surgery, chemotherapy, radiotherapy and targeted treatment.

Cytokine is a kind of bioactive cellular immune regulatory protein produced by immune cells and their related cells, which plays an important role in regulating tumor immunogenicity and anti-tumor immunity. According to the biological activity of cytokines, they can be divided into five categories: interferon (IFN), interleukin (IL), hematopoietic factor, transforming growth factor (TGF) and tumor necrosis factor. Cytokine therapy is one of the current research directions of tumor immunotherapy, and its mechanism of action is mainly immune stimulation and direct effect on tumor cells.

Il-36 belongs to the family of IL-1, which is divided into three subtypes: il-36 α, il-36 β and il-36 γ. They share the same receptor il-36r and receptor inhibitor il-36rn. Previous studies have confirmed that il-36 γ plays an important role in IL-23 / il-17-controlled inflammation and anti BCG Th1 immune response. However, the effect of il-36 γ on tumor immunity is not clear.

In this paper, the researchers confirmed that il-36 γ can stimulate CD8 + T cells, NK cells and δ T cells in combination with TCR signal and / or IL-12. Importantly, they found that il-36 γ can play a significant anti-tumor effect in vivo and transform the tumor microenvironment to support the elimination of tumor. In addition, il-36 γ can strongly enhance the efficacy of tumor vaccine. The researchers confirmed that the expression of il-36 γ was negatively correlated with the progression of human melanoma and lung cancer.

The new study established the role of il-36 γ in promoting anti-tumor immune response, and showed its potential to be transformed into a cancer immunotherapy.